Physician profile
Ron Mitzner
NPI 1083828495
$8,175.70
in general payments reported to CMS, 2019-2025
34 companies · $1,639 in 2025
The $1,639 reported for 2025 was more than what 87% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $295 · 2021: $485 · 2022: $1,534 · 2023: $2,006 · 2024: $1,666 · 2025: $1,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,310.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,518.44 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,229.82 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,225.22 | 2021-2025 | Nucala |
| Optinose US, INC. | $943.94 | 2019-2025 | |
| Aerin Medical INC. | $861.16 | 2019-2025 | |
| Inspire Medical Systems, INC. | $268.32 | 2023-2025 | Inspire |
| Stryker Corporation | $266.86 | 2019-2025 | Clarifix Cryotherapy Device, Scopis Ent, Xpress Ent Dilation System |
| Neurent Medical Limited | $243.59 | 2023 | Neuromark Radiofrequency Console, Neuromark Device |
| Blueprint Medicines Corporation | $230.01 | 2023-2024 | Ayvakit |
| Grifols USA, LLC | $194.48 | 2020-2025 | Xembify |
| Hikma Pharmaceuticals USA | $182.00 | 2022-2025 | Ryaltris |
| Ars Pharmaceuticals Operations, INC. | $129.45 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $114.30 | 2024-2025 | |
| Acclarent, INC | $99.55 | 2019-2023 | Trudi Nav Cable |
| Aimmune Therapeutics, INC. | $69.30 | 2020-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $64.41 | 2024-2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Takeda Pharmaceuticals U.S.A., INC. | $62.84 | 2021-2022 | |
| Smith+Nephew, INC. | $52.73 | 2019 | |
| Alk-Abello, INC | $50.75 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $43.58 | 2025 | Xhance |
| Octapharma USA, INC. | $40.45 | 2021-2024 | Cutaquig |
| Merck Sharp & Dohme LLC | $39.70 | 2023 | |
| Leo Pharma INC. | $28.88 | 2022 | |
| Phathom Pharmaceuticals, INC. | $26.79 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $26.11 | 2025 | Tezspire |
| Aytu Biopharma, INC. | $21.77 | 2020 | |
| Photonicare INC | $21.57 | 2024 | Otosight Middle Ear Scope |
| Phadia US INC. | $19.36 | 2023 | Immunocap |
| Medtronic, INC. | $19.00 | 2024 | Propel |
| Circassia INC. | $18.89 | 2019 | |
| Intersect Ent, INC. | $18.68 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.66 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.09 | 2019 | |
| Glenmark Therapeutics INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ron Mitzner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.